Denali Therapeutics (NASDAQ: DNLI) Stock Analysis: Navigating Setbacks and Seizing Growth Opportunities

Font: Financial Modeling Prep  • May 22, 2026

• Despite a recent setback with a Parkinson's disease drug, Denali Therapeutics Inc. (NASDAQ: DNLI) has a significant $35.00 price target from Morgan Stanley, implying substantial 87.77% potential upside.
• The company achieved its first landmark FDA approval for AVLAYAH, a treatment for Hunter syndrome, marking a pivotal transition and demonstrating pipeline success.
• Savvy institutional investors, like ADAR1 Capital Management, are showing strong confidence with a substantial $36.20 million investment following Denali's first drug approval.

Denali Therapeutics Inc. (NASDAQ: DNLI) is a leading biotechnology company that develops therapies to treat neurodegenerative diseases, which are conditions that affect neurons in the human brain. The company's stock is currently trading at $18.64 per share and has a market capitalization of approximately $2.96 billion, with a daily trading volume of over 3.38 million shares.

On May 22, 2026, Morgan Stanley issued a stock price target of $35.00 for Denali. A price target is an analyst's projection of a stock's future value. At the time, the stock was trading at $18.64, meaning this new target implies a potential upside, or increase in value, of approximately 87.77% for investors.

This optimistic outlook exists despite recent setbacks. As highlighted by Zacks, Denali's shares dropped 8% after a partnered study with Biogen for a Parkinson's disease drug, BIIB122, failed. The study did not meet its primary or secondary goals, causing the companies to stop its development for most cases of the disease.

However, Denali is seeing success elsewhere in its pipeline. The company recently received its first FDA approval for the drug AVLAYAH, which treats Hunter syndrome. According to MarketBeat, Denali's Chief Operating Officer noted that the drug's launch is "proceeding ahead of expectations," marking a significant transition for the company.

This progress has attracted institutional investors. A recent SEC filing shows that prominent hedge fund ADAR1 Capital Management made a large investment of approximately $36.20 million in Denali, purchasing over 1.80 million shares. As reported by The Motley Fool, this move shows significant confidence from a large investor following the company's first drug approval.